Lycia Therapeutics Raises $75 Million in Oversubscribed Series D Financing

Corporate Action

โดย GlobeNewswire·Read original

Summary · why it matters

Lycia Therapeutics has completed an oversubscribed $75 million Series D financing co-led by Janus Henderson Investors and Balyasny Asset Management, with new participation from Adage Capital Management, HBM Healthcare Investments, and OrbiMed, alongside continued support from existing investors including Eli Lilly and Company. The proceeds will advance its LYTAC pipeline, specifically LCA-0061 for food allergy and LCA-0321 for Graves' disease, toward early clinical proof-of-concept. The company also appointed Amy Bachrodt as Chief Financial Officer and promoted Karen Flick to General Counsel.